Science 37, which recently was in buzz for its deal with Novartis has some what of a unique offering when it comes to clinical trials.
Company has inked a deal with Novartis for 10 new clinical trials involving usage of its new operating model meta site, which is based on its mobile research platform NORA.
Company under the leadership of Belinda Tan had closed cumulative funding amount of USD 66 million in year 2016 & 2017. Early round of investments that Science 37 closed in 2015 involved dRx capital, joint investment venture of Novartis.
Science 37 has also been able to impress other pharmaceutical behemoths such as Otsuka Pharmaceuticals, this goes about highlighting potential that Science 37 carries with its amazing service portfolio.